GSK Plans £1 Bil. In Cuts As Respiratory Strategy Fails To Deliver
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s biggest drug maker said it will cut costs by £1 billion in three years as sales of its blockbuster Advair continued to fall under increasing pricing pressure; the company also unveiled key management changes, including within its top R&D slots.
You may also be interested in...
Emerging Markets Earnings: GSK CEO Witty Opens Up On China
GlaxoSmithKline’s CEO Andrew Witty opens up on emerging markets and China after some sly prompting from an analyst broke down what has been a hard stone wall.
GSK Sets Sights On ViiV HIV Spin-Out In 2016
CEO Andrew Witty said the company will explore the possibility of an IPO of a minority stake in ViiV, an HIV-centric joint venture with Pfizer and Shionogi, as the company continues to reshape its business.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.